Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 02/21/2025 | CALL | $5.00 | 2,101 | +779 | +58.93% |
| 02/21/2025 | PUT | $4.50 | 1,354 | +205 | +17.84% |
| 02/21/2025 | CALL | $5.50 | 959 | +203 | +26.85% |
| 01/16/2026 | CALL | $5.00 | 1,684 | +123 | +7.88% |
| 01/15/2027 | CALL | $5.50 | 129 | +104 | +416.00% |
| 06/20/2025 | CALL | $5.00 | 1,173 | +98 | +9.12% |
| 01/17/2025 | PUT | $4.00 | 642 | -40 | -5.87% |
| 02/21/2025 | PUT | $1.50 | 40 | -55 | -57.89% |
| 01/17/2025 | PUT | $2.50 | 4,717 | -100 | -2.08% |
| 01/17/2025 | CALL | $5.50 | 2,877 | -143 | -4.74% |
| 03/21/2025 | CALL | $7.50 | 4,094 | -208 | -4.83% |
| 03/21/2025 | CALL | $5.00 | 8,348 | -314 | -3.63% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
| Name | Pct Held | Shares | Total |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.43% | 1.48M | 4.72M |
| iShares Russell 2000 ETF | 1.06% | 1.09M | 3.48M |
| Vanguard Extended Market Index Fund | 0.75% | 770.08k | 2.46M |
| iShares Russell 2000 Growth ETF | 0.41% | 427.99k | 1.37M |
| iShares NASDAQ Biotechnology ETF | 0.41% | 420.07k | 1.34M |
| Fidelity Small Cap Index Fund | 0.34% | 350.79k | 1.12M |
| Fidelity Extended Market Index Fund | 0.24% | 248.66k | 793.22k |
| Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 0.20% | 210.69k | 672.09k |
| Vanguard Health Care Index Fund | 0.19% | 193.94k | 618.67k |
| Schwab Capital Trust-Small Cap Index Fund | 0.13% | 131.72k | 420.19k |
HUMA INVESTOR ALERT: Kirby McInerney LLP Reminds Humacyte, Inc. Investors of Looming Lead Plaintiff Deadline in Class Action Lawsuit
01/10 12:00 pm
GlobeNewswire Inc.
Read moreHUMA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
01/06 05:00 pm
GlobeNewswire Inc.
Read moreROSEN, HIGHLY RECOGNIZED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA
01/05 02:23 pm
GlobeNewswire Inc.
Read moreDEADLINE ALERT for PACS, HAS, ASML, HUMA: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
01/03 01:00 pm
GlobeNewswire Inc.
Read moreHumacyte, Inc. (HUMA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
01/02 05:06 pm
Benzinga
Read moreDEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors of Humacyte to Contact Us to Have Their Losses Evaluated Today
12/31 10:21 am
GlobeNewswire Inc.
Read moreROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA
12/30 07:54 pm
GlobeNewswire Inc.
Read moreROSEN, NATIONAL TRIAL LAWYERS, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA
12/26 03:41 pm
GlobeNewswire Inc.
Read moreHUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit
12/26 01:32 pm
Benzinga
Read moreHUMA Lead Plaintiff Deadline Approaching – Contact Robbins LLP for Information About the Class Action Against Humacyte, Inc.
12/24 04:58 pm
GlobeNewswire Inc.
Read moreROSEN, A LONGSTANDING FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA
12/23 11:55 pm
GlobeNewswire Inc.
Read moreHUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm
12/23 11:27 am
Benzinga
Read moreROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA
12/20 11:58 pm
GlobeNewswire Inc.
Read moreUS Stocks To Open Lower As Traders Brace For 'Triple Witching' Hour: Analyst Says End Of The Year Recovery 'Would Not Surprise Anyone'
12/20 06:37 am
Benzinga
Read moreHumacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma
12/19 11:47 pm
GlobeNewswire Inc.
Read moreHUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Humacyte, Inc. and Encourages Investors to Contact the Firm
12/19 10:00 pm
GlobeNewswire Inc.
Read moreDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte
12/19 08:23 pm
GlobeNewswire Inc.
Read moreHUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit
12/19 02:26 pm
Benzinga
Read moreGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Humacyte, Inc. (HUMA)
12/12 01:56 pm
GlobeNewswire Inc.
Read moreHumacyte’s (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman
12/12 12:48 pm
GlobeNewswire Inc.
Read moreHUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit
12/11 08:21 pm
Benzinga
Read moreInvestors in Humacyte, Inc. Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your Rights – HUMA
12/11 02:00 pm
GlobeNewswire Inc.
Read moreROSEN, LEADING INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA
12/06 11:56 am
GlobeNewswire Inc.
Read moreROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA
12/03 06:41 pm
GlobeNewswire Inc.
Read more全球頂尖法律事務所 ROSEN 鼓勵 Humacyte, Inc. 投資者在對 HUMA 提出證券集體訴訟的重要截止日期之前聘請律師
11/30 02:49 pm
GlobeNewswire Inc.
Read moreROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA
11/30 02:49 pm
GlobeNewswire Inc.
Read moreROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA
11/27 08:15 pm
GlobeNewswire Inc.
Read moreHUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit
11/27 04:38 pm
Benzinga
Read moreHUMA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
11/26 05:00 pm
GlobeNewswire Inc.
Read moreThe Gross Law Firm Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 – HUMA
11/26 02:20 pm
GlobeNewswire Inc.
Read moreHUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Humacyte, Inc. and Encourages Investors to Contact the Firm
11/25 10:00 pm
GlobeNewswire Inc.
Read moreHumacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)
11/22 09:00 am
GlobeNewswire Inc.
Read moreGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Humacyte, Inc. (HUMA)
11/21 04:04 pm
Benzinga
Read moreHUMACYTE, INC. (NASDAQ: HUMA) INVESTOR ALERT: Investors With Large Losses in Humacyte, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
11/21 01:00 pm
GlobeNewswire Inc.
Read moreKirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Investors
11/19 06:03 pm
Benzinga
Read moreHUMA CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Humacyte, Inc.
11/18 05:55 pm
Benzinga
Read moreHumacyte’s (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman
11/15 02:32 pm
GlobeNewswire Inc.
Read moreHumacyte (HUMA) Faces Questions After FDA Inspection – Hagens Berman
11/11 05:37 pm
GlobeNewswire Inc.
Read moreHumacyte (HUMA) Faces Questions After FDA Inspection – Hagens Berman
10/24 02:55 pm
GlobeNewswire Inc.
Read moreINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors
10/22 09:03 pm
Benzinga
Read moreThe Law Offices of Frank R. Cruz Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors
10/22 07:16 pm
Benzinga
Read moreHumacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on September 30, 2024
09/26 05:26 pm
GlobeNewswire Inc.
Read moreHumacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors
06/21 06:15 pm
Zacks Investment Research
Read moreWall Street Breakfast: The Week Ahead
05/19 06:35 am
Seeking Alpha
Read moreHumacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024
03/26 04:05 pm
GlobeNewswire Inc.
Read more